Research graph
References from A novel provocation protocol to identify nocebo effects in clinical practice—a proof-of-concept n-of-1 study. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1007/978-3-642-74904-9
10.1007/978-3-642-74904-9 · 1990 · External reference
EAACI/ENDA position paper on drug provocation testing
10.1111/all.15996 · 2024 · External reference
Nonspecific medication side effects and the nocebo phenomenon
10.1001/jama.287.5.622 · 2002 · External reference
Avoiding nocebo effects to optimize treatment outcome
10.1001/jama.2014.8342 · 2014 · External reference
The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil
10.1126/scitranslmed.3001244 · 2011 · External reference
10.1016/s2215-0366(25)00340-2
10.1016/s2215-0366(25)00340-2 · External reference
Case Report: practical approach to unmask unspecific adverse effects under lipid-lowering medication
10.3389/fcvm.2025.1604129 · 2025 · External reference
Reliability and validity of a vertical numerical rating scale supplemented with a faces rating scale in measuring fatigue after stroke
10.1186/s12955-015-0290-9 · 2015 · External reference
The nocebo effect
10.1146/annurev-pharmtox-022723-112425 · 2024 · External reference
Placebo and nocebo effects
10.1056/nejmra1907805 · 2020 · External reference
The nocebo effect and its relevance for clinical practice
10.1097/psy.0b013e3182294a50 · 2011 · External reference
Placebos in clinical practice and research
10.1136/jme.22.3.140 · 1996 · External reference
The placebo and nocebo responses in clinical trials in inflammatory bowel diseases
10.3389/fphar.2021.641436 · 2021 · External reference
Novel study designs to investigate the placebo response
10.1186/1471-2288-11-90 · 2011 · External reference
The placebo response in medicine: minimize, maximize or personalize?
10.1038/nrd3923 · 2013 · External reference
Validity of four pain intensity rating scales
10.1016/j.pain.2011.07.005 · 2011 · External reference
The cognitive difficulties scale (CDS): psychometric characteristics in a clinical referral sample
10.1017/s1355617720001058 · 2021 · External reference
Interaction between drug and placebo effects: a cross-over balanced placebo design trial
10.1186/1745-6215-11-110 · 2010 · External reference
Drug placebo interaction effect may bias clinical trials interpretation: hybrid balanced placebo and randomized placebo-controlled design
10.1186/s12874-016-0269-1 · 2016 · External reference
Nocebo phenomena in medicine: their relevance in everyday clinical practice
10.3238/arztebl.2012.0459 · 2012 · External reference
Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials
10.1136/bmj.n135 · 2021 · External reference
Expectancy effects, failure of blinding integrity, and placebo response in trials of treatments for psychiatric disorders a narrative review
10.1001/jamapsychiatry.2025.0085 · 2025 · External reference
Drug allergy: a 2022 practice parameter update
10.1016/j.jaci.2022.08.028 · 2022 · External reference
Confirming false adverse reactions to drugs by performing individualized, randomized trials
2002 · External reference
Nocebo effect during letrozole desensitization: a case report
10.7759/cureus.87841 · 2025 · External reference
Causality assessment of adverse effects when is re-challenge ethically acceptable?
10.2165/00002018-200124110-00001 · 2001 · External reference
Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions
2004 · External reference
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
10.2217/pme.11.7 · 2011 · External reference
The nocebo effect during oral challenge in subjects with adverse drug reactions
2008 · External reference
Randomised controlled trials may underestimate drug effects: balanced placebo trial design
10.1371/journal.pone.0084104 · 2014 · External reference
Inclusion of authorized deception in the informed consent process does not affect the magnitude of the placebo effect for experimentally induced pain
10.1016/j.pain.2009.12.004 · 2010 · External reference
Modifying informed consent to help address functional unmasking in psychedelic clinical trials
10.1001/jamapsychiatry.2024.4312 · 2025 · External reference
Patient perspectives on statin intolerance, attribution of the nocebo effect and use of N=1-interventions: a qualitative focus group study
10.1016/j.atherosclerosis.2025.120514 · 2025 · External reference
Deception in research on the placebo effect
10.1371/journal.pmed.0020262 · 2005 · External reference
A method for estimating the probability of adverse drug reactions
10.1038/clpt.1981.154 · 1981 · External reference
Placebo and nocebo in clinical practice: an online cross-sectional survey of healthcare professionals from European countries on views, practices and training needs
10.1371/journal.pone.0338905 · 2026 · External reference
Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
10.1002/jcsm.12344 · 2018 · External reference
Rethinking evidence in contemporary evidence-based medicine: a critical examination into emerging forms of clinical practice
10.1111/jep.70369 · 2026 · External reference
Nocebo effect: a bias in clinical practice-an ethical approach
10.1097/mjt.0000000000001730 · 2024 · External reference
Noble Humbug? hard and soft laws on clinical placebo use
10.3389/fpsyg.2025.1520664 · 2025 · External reference
The balanced placebo design: methodological considerations
10.1016/0306-4603(81)90003-4 · 1981 · External reference
Understanding the role of expectancy, anticipatory anxiety, and attention bias in nocebo hyperalgesia: a gaze-contingent attention bias modification study
10.1016/j.jpain.2023.10.016 · 2024 · External reference
The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies
10.1038/clpt.1993.190 · 1993 · External reference
Assessing cognitive impairment using PROMIS® applied cognition-abilities scales in a medical outpatient sample
10.1016/j.psychres.2014.12.043 · 2015 · External reference
Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatry
10.1016/s2215-0366(26)00018-0 · 2026 · External reference
Montreal cognitive assessment as a screening tool: influence of performance and symptom validity
10.1212/cpj.0000000000000604 · 2019 · External reference
Deception in the pursuit of science
10.1001/archinte.164.6.597 · 2004 · External reference
Unresolved reference
2014 · External reference
Deception in the pursuit of science
10.1001/archinte.164.6.597 · ExternalCitation · doi-reference
Avoiding nocebo effects to optimize treatment outcome
10.1001/jama.2014.8342 · ExternalCitation · doi-reference
Nonspecific medication side effects and the nocebo phenomenon
10.1001/jama.287.5.622 · ExternalCitation · doi-reference
Modifying informed consent to help address functional unmasking in psychedelic clinical trials
10.1001/jamapsychiatry.2024.4312 · ExternalCitation · doi-reference
Expectancy effects, failure of blinding integrity, and placebo response in trials of treatments for psychiatric disorders a narrative review
10.1001/jamapsychiatry.2025.0085 · ExternalCitation · doi-reference
Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
10.1002/jcsm.12344 · ExternalCitation · doi-reference
10.1007/978-3-642-74904-9
10.1007/978-3-642-74904-9 · ExternalCitation · doi-reference
The balanced placebo design: methodological considerations
10.1016/0306-4603(81)90003-4 · ExternalCitation · doi-reference
Patient perspectives on statin intolerance, attribution of the nocebo effect and use of N=1-interventions: a qualitative focus group study
10.1016/j.atherosclerosis.2025.120514 · ExternalCitation · doi-reference
Drug allergy: a 2022 practice parameter update
10.1016/j.jaci.2022.08.028 · ExternalCitation · doi-reference
Understanding the role of expectancy, anticipatory anxiety, and attention bias in nocebo hyperalgesia: a gaze-contingent attention bias modification study
10.1016/j.jpain.2023.10.016 · ExternalCitation · doi-reference
Inclusion of authorized deception in the informed consent process does not affect the magnitude of the placebo effect for experimentally induced pain
10.1016/j.pain.2009.12.004 · ExternalCitation · doi-reference
Validity of four pain intensity rating scales
10.1016/j.pain.2011.07.005 · ExternalCitation · doi-reference
Assessing cognitive impairment using PROMIS® applied cognition-abilities scales in a medical outpatient sample
10.1016/j.psychres.2014.12.043 · ExternalCitation · doi-reference
10.1016/s2215-0366(25)00340-2
10.1016/s2215-0366(25)00340-2 · ExternalCitation · doi-reference
Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatry
10.1016/s2215-0366(26)00018-0 · ExternalCitation · doi-reference
The cognitive difficulties scale (CDS): psychometric characteristics in a clinical referral sample
10.1017/s1355617720001058 · ExternalCitation · doi-reference
A method for estimating the probability of adverse drug reactions
10.1038/clpt.1981.154 · ExternalCitation · doi-reference
The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies
10.1038/clpt.1993.190 · ExternalCitation · doi-reference
The placebo response in medicine: minimize, maximize or personalize?
10.1038/nrd3923 · ExternalCitation · doi-reference
Placebo and nocebo effects
10.1056/nejmra1907805 · ExternalCitation · doi-reference
Nocebo effect: a bias in clinical practice-an ethical approach
10.1097/mjt.0000000000001730 · ExternalCitation · doi-reference
The nocebo effect and its relevance for clinical practice
10.1097/psy.0b013e3182294a50 · ExternalCitation · doi-reference
EAACI/ENDA position paper on drug provocation testing
10.1111/all.15996 · ExternalCitation · doi-reference
Rethinking evidence in contemporary evidence-based medicine: a critical examination into emerging forms of clinical practice
10.1111/jep.70369 · ExternalCitation · doi-reference
The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil
10.1126/scitranslmed.3001244 · ExternalCitation · doi-reference
Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials
10.1136/bmj.n135 · ExternalCitation · doi-reference
Placebos in clinical practice and research
10.1136/jme.22.3.140 · ExternalCitation · doi-reference
The nocebo effect
10.1146/annurev-pharmtox-022723-112425 · ExternalCitation · doi-reference
Novel study designs to investigate the placebo response
10.1186/1471-2288-11-90 · ExternalCitation · doi-reference
Interaction between drug and placebo effects: a cross-over balanced placebo design trial
10.1186/1745-6215-11-110 · ExternalCitation · doi-reference
Drug placebo interaction effect may bias clinical trials interpretation: hybrid balanced placebo and randomized placebo-controlled design
10.1186/s12874-016-0269-1 · ExternalCitation · doi-reference
Reliability and validity of a vertical numerical rating scale supplemented with a faces rating scale in measuring fatigue after stroke
10.1186/s12955-015-0290-9 · ExternalCitation · doi-reference
Montreal cognitive assessment as a screening tool: influence of performance and symptom validity
10.1212/cpj.0000000000000604 · ExternalCitation · doi-reference
Deception in research on the placebo effect
10.1371/journal.pmed.0020262 · ExternalCitation · doi-reference
Randomised controlled trials may underestimate drug effects: balanced placebo trial design
10.1371/journal.pone.0084104 · ExternalCitation · doi-reference
Placebo and nocebo in clinical practice: an online cross-sectional survey of healthcare professionals from European countries on views, practices and training needs
10.1371/journal.pone.0338905 · ExternalCitation · doi-reference
Causality assessment of adverse effects when is re-challenge ethically acceptable?
10.2165/00002018-200124110-00001 · ExternalCitation · doi-reference
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
10.2217/pme.11.7 · ExternalCitation · doi-reference
Nocebo phenomena in medicine: their relevance in everyday clinical practice
10.3238/arztebl.2012.0459 · ExternalCitation · doi-reference
Case Report: practical approach to unmask unspecific adverse effects under lipid-lowering medication
10.3389/fcvm.2025.1604129 · ExternalCitation · doi-reference
The placebo and nocebo responses in clinical trials in inflammatory bowel diseases
10.3389/fphar.2021.641436 · ExternalCitation · doi-reference
Noble Humbug? hard and soft laws on clinical placebo use
10.3389/fpsyg.2025.1520664 · ExternalCitation · doi-reference
Nocebo effect during letrozole desensitization: a case report
10.7759/cureus.87841 · ExternalCitation · doi-reference
